Clinical Insights • Hormone Therapy

Is Hormone Therapy Safe? What the Research Really Says About HRT Benefits and Risks

Scared off hormone therapy by the headlines? Here’s what the research actually shows about HRT benefits and risks, and what decides whether it’s right for you.


For many women, the hormone therapy conversation never happened.

Not because it wasn’t right for them. Because they were scared out of ever asking.

Breast cancer. Heart disease. Dementia. Those words hung over hormone therapy for more than twenty years. They stopped millions of women from asking about it, and millions of providers from bringing it up. Meanwhile, hot flashes got managed with whatever else was available, sleep problems got treated with sedatives, and mood changes got chalked up to stress.

The real picture is more nuanced than the headline that scared you.

If you closed the door on hormone therapy years ago because of what you heard, the conversation is worth reopening. Not because hormone therapy is risk-free, and not because it’s right for everyone, but because you deserve the full picture.

This post covers how we got here, what the research shows now, the real benefits and risks, and what I look at from a functional medicine perspective to help women decide. Numbers in brackets point to the references at the end.

Woman sitting on her bed applying a hormone therapy patch
Hormone therapy decisions should be based on the full picture, not a twenty-year-old headline.
How We Got Here

The 2002 Headline That Changed Everything

In 2002, the Women’s Health Initiative (WHI), one of the largest hormone therapy trials ever done, stopped its estrogen-plus-progestin arm early after finding small increases in breast cancer, heart disease, stroke, and blood clots.[1] The headlines were enormous. Within months, millions of women stopped taking hormones, and prescribing fell sharply.

“26% Higher Risk” in Absolute Terms~8 in 10,000

additional breast cancer cases per year of use

Here’s what often got lost:

01

The Women Were Older

The average participant was 63, and most were well past menopause. That’s very different from a woman starting hormone therapy at 50 for hot flashes.

02

One Specific Regimen Was Tested

Oral conjugated equine estrogens combined with a synthetic progestin (medroxyprogesterone acetate). That’s not what most women are prescribed today.

03

Relative Risk Sounds Bigger Than Absolute Risk

“26% higher breast cancer risk” sounds frightening. In absolute terms, the difference was about 8 additional cases per 10,000 women taking it for a year.[1]

None of that makes the findings meaningless. They’re real. It means the headline was one chapter, and the story kept going.

What We Know Now

Three Things That Changed the Picture

1 • Who

Timing Matters

When analyses looked at women by age, the pattern shifted. Women who started hormone therapy under 60, or within about ten years of menopause, had a more favorable balance of benefits and risks than women who started later.[2], [3] Current expert guidance reflects that.[3]

2 • What

The Type and the Route Matter

  • In the WHI’s estrogen-alone arm (women without a uterus), breast cancer risk was not increased,[4] and long-term follow-up even showed a lower rate.[5]
  • Over 18 years of follow-up, hormone therapy did not increase overall mortality.[6]
  • Transdermal estrogen (patch or gel) appears to carry a lower risk of blood clots[7] and stroke[8] than oral estrogen, because it bypasses first-pass processing in the liver.
  • Observational studies suggest micronized progesterone may carry less breast cancer risk than some synthetic progestins, though this isn’t proven in randomized trials.[9], [10]
3 • How Much

Dose and Duration, Reviewed Regularly

Guidelines call for the lowest effective dose for the shortest time that meets your goals, reviewed regularly, not a one-size-fits-all prescription.[3] (Here’s how hormone therapy dosing really works.)

At a Glance

The Benefits and Risks

BenefitsWhat the Research Shows
Hot flashes and night sweatsThe most effective treatment available; roughly a 75% reduction in frequency versus placebo[11]
Vaginal and urinary symptomsEffective, and low-dose vaginal estrogen works with minimal absorption
BoneReduces bone loss and lowers fracture risk[12]
Sleep and moodOften improves sleep and, for some women in perimenopause, mood (see anxiety or perimenopause?)
Risks & LimitsWhat the Research Shows
Blood clotsOral estrogen increases risk; transdermal appears lower[7]
StrokeSmall increase with oral estrogen, lower with transdermal[8]
Breast cancerSmall increase with long-term combined estrogen and progestogen use; not seen with estrogen alone in the WHI[4], [9]
Heart diseaseNot recommended to prevent heart disease. Starting under 60 or near menopause is generally considered favorable[2], [3]
DementiaNot recommended to prevent dementia. In women 65 and older who started combined hormones, risk was higher[13]

For a closer look at breast cancer specifically, read my post on hormone therapy and breast cancer.

Cover of What’s Your Hormone Type?, the free estrogen and progesterone balance quiz from Farmacy Counter
Free Assessment

Not Sure Whether This Applies to You?

Hormone therapy is one option among several. If you’re not sure where your symptoms fit, my free Hormone Type Assessment is a short quiz that helps you see whether your symptoms point toward:

  • Estrogen dominance
  • Estrogen deficiency
  • Progesterone deficiency
  • A mixed pattern
Take the Free Assessment →
It’s Personal

What I Look At

The question isn’t “is hormone therapy safe?” It’s “is it right for you, at your age, with your history?” That’s a personal risk and benefit conversation. These are the pieces I look at:

  1. 1

    Your Personal and Family History

    Breast, ovarian, and uterine cancers; blood clots; stroke; heart disease; and migraine with aura.

  2. 2

    Your Timeline

    How old you are, and how long since your last period.

  3. 3

    Your Numbers

    Blood pressure, cholesterol and triglycerides, fasting glucose, insulin, and A1c, plus liver enzymes. Cardiometabolic health shapes your risk.

  4. 4

    Your Screenings

    An up-to-date mammogram and breast density, plus cervical and colon screening. (See what proactive breast health looks like.)

  5. 5

    Your Lifestyle Risk Factors

    Alcohol, weight, smoking, activity, and sleep. For example, alcohol raises breast cancer risk in a dose-related way,[14] and it’s something you control, whatever you decide about hormones. (More on alcohol.)

  6. 6

    Your Symptoms and Goals

    What bothers you most, and what you hope to gain.

Four Working Patterns

I also use my four working patterns to organize the picture:

Dysregulated Rhythm

Hot flashes, night sweats, wired at night, tired by day

Deficiency & Depletion

Low energy, dry skin, hair shedding, slow recovery

Traffic Misdirection

Blood sugar swings, cravings, stubborn midsection weight

Overloaded Clearance

Bloating, breast tenderness, puffiness, alcohol hitting harder

These are clues that organize questions. They don’t diagnose a cause.

Safety First

When Hormone Therapy Isn’t the Right Fit

Hormone therapy isn’t appropriate for everyone. Your provider will likely advise against it, or approach it very carefully, if you have:

  • A history of breast cancer or other estrogen-sensitive cancer (this depends on the type and needs coordination with your oncologist)
  • A history of blood clots or stroke
  • Unexplained vaginal bleeding
  • Active liver disease
  • Heart disease

If you have a uterus and take estrogen, you also need a progestogen alongside it to protect the lining.

When It’s Right

How It’s Done Safely

  1. 1

    Start Low and Adjust

    Aim for the lowest effective dose. I cover this in my post on how dosing really works.

  2. 2

    Choose the Form That Fits Your Risk

    Transdermal is often preferred if you have clot or cardiovascular risk factors.

  3. 3

    Include a Progestogen If You Have a Uterus

    It protects the uterine lining.

  4. 4

    Reassess Regularly

    At least yearly, with your symptoms, blood pressure, and screenings.

  5. 5

    Keep Your Screenings Current

    Mammograms, cervical, and colon screening.

  6. 6

    Build the Foundations Too

    Strength training, protein, sleep, and less alcohol support your bones, mood, and metabolism whether or not you use hormones. (Why muscle matters.)

If You Choose Not to Use Hormones

That’s a valid choice too. Non-hormonal options can help with hot flashes, and they’re worth discussing with your provider.[15] Sleep, strength training, and managing triggers help too. The goal is a plan you feel good about.

Questions to Bring to Your Provider
  • “Based on my age, history, and family history, what are my personal benefits and risks?”
  • “How long since my last period, and does that change the picture?”
  • “Would a patch or gel make more sense for me than a pill?”
  • “What would we monitor, and how often?”
  • “If I’d rather not use hormones, what are my options?”
When to Get Help Right Away

If you’re already on hormone therapy, call your provider or seek emergency care promptly for leg pain or swelling on one side, chest pain, shortness of breath, sudden vision changes, a sudden severe headache, weakness, or trouble speaking. Also report heavy or unexpected vaginal bleeding.

Reopening the Door

You Deserve the Full Picture, Not Just the Fear

A decision you made years ago, based on a headline, doesn’t have to be the final one. Maybe hormone therapy isn’t right for you. Maybe it is. Either way, you deserve to make that choice with the full picture.

If you haven’t yet, start with the free Hormone Type Assessment. And if you’d rather talk through your own situation, I offer a free discovery call. No pressure, just a conversation about whether functional medicine is the right next step for you.

Book Your Free Discovery Call →

To your health and vitality, Dr. Ryan

Common Questions

Frequently Asked Questions

Is hormone therapy safe?

For many healthy women who start hormone therapy under 60 or within about ten years of menopause, the benefits generally outweigh the risks. It isn’t right for everyone, and the decision depends on your age, health history, and the type and route of therapy.

Does hormone therapy cause breast cancer?

Long-term combined estrogen and progestogen use is linked to a small increase in breast cancer risk, about 8 additional cases per 10,000 women per year in the WHI. Estrogen alone did not increase risk in the WHI, and long-term follow-up showed a lower rate.

Is a patch safer than a pill?

Transdermal estrogen (patch or gel) appears to carry a lower risk of blood clots and stroke than oral estrogen because it bypasses first-pass processing in the liver. It’s often preferred for women with clot or cardiovascular risk factors.

What did the Women’s Health Initiative actually find?

The 2002 WHI estrogen-plus-progestin trial found small increases in breast cancer, heart disease, stroke, and blood clots. Participants averaged 63 and were mostly well past menopause, and one specific oral regimen was tested. Later analyses showed timing, type, and route matter.

Who shouldn’t take hormone therapy?

Women with a history of breast or other estrogen-sensitive cancer, blood clots, stroke, heart disease, active liver disease, or unexplained vaginal bleeding usually aren’t good candidates, or need a very careful approach with their providers.

For educational purposes only. Not a diagnosis, and not a substitute for care from your healthcare provider. Do not start, stop, or change any medication, including hormone therapy, without talking with your prescriber.

References
  1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
  2. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.
  3. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.
  4. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
  5. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
  6. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927–938.
  7. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
  8. Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.
  9. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
  10. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
  11. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978.
  12. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738.
  13. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651–2662.
  14. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies. Br J Cancer. 2002;87(11):1234–1245.
  15. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.